Microbiome Therapeutics Market Trends

Growth Drivers

• Worldwide Growing Prevalence of Diabetes – Diabetes is a chronic disorder that arises when the pancreas does not make enough insulin or when the body does not use the insulin adequately that is produced. The gut microbiota has been related to the development of several metabolic syndromes including diabetes through reduced glucose tolerance and insulin sensitivity. Hence, the rising prevalence of diabetes is estimated to propel the growth of the market over the forecast period. For instance, in 2021, diabetes affected around 540 million individuals throughout the world. Moreover, by 2030, this figure is expected to climb to nearly 648 million.

• An Upsurge in Obesity - Obesity is a complicated condition defined by an excess of body fat. It's a medical condition that escalates the chance of getting other diseases and health issues, including heart disease, high blood pressure, and some sort of cancer. The gut microbiota may induce obesity through a multitude of processes, comprising energy balance control, LPS-stimulated inflammation, bile acids, and fat deposition control. Hence, the surge in obesity is anticipated to propel market growth in the coming years. As per the World Health Organization (WHO) figures, obesity affected more than 1 billion people across the globe by 2022, comprising 650 million adults, 340 million adolescents, and 39 million children.

• Increasing Ratio of Autoimmune Diseases – Globally, the ratio of several kinds of autoimmune disorders such as celiac disease, Addison disease, multiple sclerosis, and so on has been growing. Any changes in the microbiota of the gastrointestinal tract have been correlated to autoimmune disorders. Thus, the surge in autoimmune diseases is projected to drive the growth of the market. For instance, currently, autoimmune disorders affecting around 24 million individuals in the United States, with women accounting for roughly 82% of those who are affected.

• An Increase in the Development of Novel Microbiome – For instance, Persephone Biosciences Inc. began developing an immune-boosting microbiome therapeutic to help mitigate and fight the novel coronavirus (SARS-CoV-2) in April 2020, as well as a potential stool-based diagnostic test to assist in determining which patients are at the greatest chance of suffering from serious medical problems and mortality after suffering from COVID-19.

• Rising Healthcare Expenditure - According to World Bank figures, worldwide healthcare expenditure increased by 9.83% in 2019.

Challenges

• Risk of Failure of the Concerned Research Projects - The research processed by numerous organizations on microbiome therapeutics is currently under different phases of clinical development. Organizations have invested massively in these research processes over the years with hopes for success in their efforts. Yet, the concern for the failure of the research projects, which would significantly impact their research investments is one of the major factor anticipated to hamper the market growth during the forecast period.

• Extreme Cost of Microbiome Therapeutics
• Stringent Regulatory Guidelines Imposed by the Government of Nations